Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Debt to Equity (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Debt to Equity for 3 consecutive years, with $0.01 as the latest value for Q4 2018.

  • On a quarterly basis, Debt to Equity fell 12.46% to $0.01 in Q4 2018 year-over-year; TTM through Dec 2018 was $0.01, a 12.46% decrease, with the full-year FY2018 number at $0.01, down 12.46% from a year prior.
  • Debt to Equity was $0.01 for Q4 2018 at Niagen Bioscience, down from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.92 in Q1 2016 to a low of $0.01 in Q4 2018.
  • A 3-year average of $0.31 and a median of $0.01 in 2017 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 12.46% in 2018; the steepest drop was 12.46% in 2018.
  • Niagen Bioscience's Debt to Equity stood at $0.92 in 2016, then tumbled by 99.38% to $0.01 in 2017, then fell by 12.46% to $0.01 in 2018.
  • Per Business Quant, the three most recent readings for NAGE's Debt to Equity are $0.01 (Q4 2018), $0.01 (Q4 2017), and $0.92 (Q1 2016).